Since VEGF concentrations in primary cervical cancer are known to affect the outcome after radiotherapy, we postulated that the addition of the potent VEGFR inhibitor cediranib to carboplatin plus paclitaxel would improve progression-free survival and response when compared with carboplatin plus paclitaxel alone. Here, VEGFA is linked to cervical cancer.